Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8IYB7
UPID:
DI3L2_HUMAN
Alternative names:
-
Alternative UPACC:
Q8IYB7; Q53S79; Q580W6; Q5XKH0; Q69YG5; Q6AW99; Q7Z4T6; Q8N9K9
Background:
DIS3-like exonuclease 2 plays a crucial role in RNA metabolism, specifically targeting RNAs polyuridylated at their 3' end for degradation. This includes mRNAs and miRNAs, essential for cellular processes such as mitosis and cell proliferation regulation. Its involvement in embryonic stem cell maintenance underscores its significance in developmental biology.
Therapeutic significance:
Perlman syndrome, characterized by congenital overgrowth and a high risk of Wilms tumor, is linked to mutations affecting DIS3-like exonuclease 2. Understanding this protein's role could pave the way for innovative treatments targeting the underlying genetic causes of this syndrome.